Phase 3 Trial Comparing BGM0504 and Semaglutide as Weekly Injections Added to Metformin or Sulfonylureas in Adults With Type 2 Diabetes

What this Trial Is About

Researchers are evaluating the efficacy and safety of BGM0504 compared to semaglutide in people with type 2 diabetes who are already taking metformin andor sulfonylureas. This phase 3 trial is conducted in China and sponsored by BrightGene Bio-Medical Technology Co., Ltd. The goal is to see how well these treatments control blood sugar levels and manage the condition. Participants receive one of three treatments 5 mg or 10 mg of BGM0504, or 1 mg of semaglutide. All drugs are given as weekly injections under the skin. The trial includes a 32-week period to measure blood sugar changes, followed by further assessments up to 52 weeks to evaluate body weight, blood sugar control, and fasting glucose levels. During the study, participants will have regular visits for blood tests to measure hemoglobin A1c and fasting glucose, along with weight checks. Researchers will monitor safety and treatment effects throughout the study. The total participation time can last up to 52 weeks, with ongoing evaluations to understand how the treatments work over time.

A Study of BGM0504 in Participants with Type 2 Diabetes